Cancer-related cognitive impairment (CRCI) is commonly experienced by individuals with
non-central nervous system cancers throughout the disease and treatment trajectory. CRCI …

Acute graft-versus-host disease (GVHD) continues to be a major cause of morbidity and
mortality after allogeneic hematopoietic cell transplant (HCT) in pediatric patients (ie …

Infantile Krabbe disease (IKD) can be treated with hematopoietic cell transplantation (HCT) if
done during the first weeks of life before symptoms develop. To facilitate this, newborn …

Hematopoietic stem cell transplant (HSCT) plays a central role in the treatment of
hematologic cancers. With the increasing survival of patients after HSCT, survivorship issues …

Chronic graft-versus-host disease (cGVHD) remains a significant complication of allogeneic
hematopoietic stem cell transplantation. Central nervous system (CNS) involvement is …

Annually,~ 50,000 patients undergo hematopoietic stem cell transplantation (HCT)
worldwide with almost 22,000 of these patients receiving HCT in the United States. HCT is a …

Slow but definite progress has been made in recognizing the differences in disease biology,
host factors, and psychosocial issues related to management of hematologic malignancies …

Background Hematopoietic stem cell transplant (HSCT) is the only curative treatment for
several pediatric non‐malignant disorders. A widely used conditioning backbone is …

Long-term fatigue and cognitive dysfunction affects 35% of allogeneic haematopoietic stem
cell transplantation (aHSCT) survivors, suggesting a dysfunctional prefrontal cortex. In this …

Hematopoietic stem cell transplantation (HCT) is a potentially curative treatment for many
hematologic conditions. Despite advances in conditioning and supportive measures …